Skip to main content

Table 1 Association of impaired fasting glucose, diabetes and their management with other cardiovascular risk factors, medication prescription and presentation in 1637 patients with peripheral artery disease

From: Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study

 

Diabetes category

  
 

1

2

3

4

5

Total

P value

Number

655 (40.0%)

460 (28.1%)

150 (9.2%)

296 (18.1%)

76 (4.6%)

1637

 

Age (years)

70.83

71.27

71.12

70.35

65.47

70.68

0.001

(63.28-76.98)

(64.64-76.69)

(66.19-76.91)

(64.22-75.01)

(59.74-72.07)

(64.13-76.43)

Male

477

352

114

226

55

1224

0.591

(72.8%)

(76.5%)

(76.0%)

(76.4%)

(72.4%)

(74.8%)

Hypertension

470

361

105

258

65

1259

<0.001

(71.8%)

(78.5%)

(70.0%)

(87.2%)

(85.5%)

(76.9%)

Ever smoker

527

399

123

238

62

1349

0.074

(80.5%)

(86.7%)

(82.0%)

(80.4%)

(81.6%)

(82.4%)

CHD

282

216

79

155

47

779

0.003

(43.1%)

(47.0%)

(52.7%)

(52.4%)

(61.8%)

(47.6%)

eGFR (mL/min/1.73 m2)

76.39

73.37

74.22

74.93

69.17

74.93

0.040

(59.40-90.43)*

(56.27-87.71)†

(51.99-87.76)‡

(56.88-88.96)§

(44.47-91.02)||

(56.97-89.35)

Presenting complaint

Asymptomatic carotid stenosis

56

35

11

30

7

139

0.772

(8.5%)

(7.6%)

(7.3%)

(10.1%)

(9.2%)

(8.5%)

Mild limb peripheral artery disease

151

91

25

89

25

381

0.001

(23.1%)

(19.8%)

(16.7%)

(30.1%)

(32.9%)

(23.3%)

Aortic and peripheral artery aneurysm

302

225

84

88

8

707

<0.001

(46.1%)

(48.9%)

(56.0%)

(29.7%)

(10.5%)

(43.2%)

Symptomatic carotid artery stenosis

90

70

15

43

8

226

0.491

(13.7%)

(15.2%)

(10.0%)

(14.5%)

(10.5%)

(13.8%)

Critical limb ischaemia

56

39

15

46

28

184

<0.001

(8.5%)

(8.5%)

(10.0%)

(15.5%)

(36.8%)

(11.2%)

Prescribed medication

Statin

392

325

92

232

61

1102

<0.001

(59.8%)

(70.7%)

(61.3%)

(78.4%)

(80.3%)

(67.3%)

Aspirin

415

311

98

226

48

1098

0.003

(63.4%)

(67.6%)

(65.3%)

(76.4%)

(63.2%)

(67.1%)

Other anti-platelets

130

90

37

72

21

350

0.194

(19.8%)

(19.6%)

(24.7%)

(24.3%)

(27.6%)

(21.4%)

Beta-blockers

199

186

53

108

28

574

0.014

(30.4%)

(40.4%)

(35.3%)

(36.5%)

(36.8%)

(35.1%)

Calcium channel blocker

155

142

50

99

27

473

0.004

(23.7%)

(30.9%)

(33.3%)

(33.4%)

(35.5%)

(28.9%)

ACE inhibitor

227

182

58

153

52

672

<0.001

(34.7%)

(39.6%)

(38.7%)

(51.7%)

(68.4%)

(41.1%)

ARB

142

94

34

94

17

381

0.005

(21.7%)

(20.4%)

(22.7%)

(31.8%)

(22.4%)

(23.3%)

Metformin

0

0

0

245

40

285

<0.001

(82.8%)

(52.6%)

(17.4%)

Other oral hypoglycaemic

0

0

0

170

26

196

<0.001

(57.4%)

(34.2%)

(12.0%)

Insulin

0

0

0

0

76

76

<0.001

(100%)

(4.6%)

Frusemide

54

43

14

39

23

173

<0.001

(8.2%)

(9.3%)

(9.3%)

(13.2%)

(30.3%)

(10.6%)

  1. Serum creatinine was unavailable on 7*, 3 †, 3 ‡, 1 § and 1|| patients therefore eGFR could not be calculated. CHD = coronary heart disease; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate. Continuous variables are presented as median and inter-quartile range and assessed using the Kruskal Wallis test. Nominal variables are presented as number and percent and analysed using the Chi-squared test.
  2. Key to patient groups:
  3. 1: No diabetes; 2: Impaired fasting glucose; 3: Non-medicated diabetes; 4: Diabetes prescribed oral hypoglycaemics only; 5: Diabetes prescribed insulin.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840